吉西他滨联合多西他赛治疗蒽环类耐药性晚期乳腺癌的临床观察  

Clinical observation of gemcitabine combined with docetaxel in the treatment of patients with advanced anthracyclineresistant breast cancer

作　　者：向其德[1] 覃事鹏 谭力[1] 林绍定 

机构地区：[1]怀化市第三人民医院肿瘤科,湖南怀化418000

出　　处：《现代医药卫生》2013年第20期3067-3068,共2页Journal of Modern Medicine & Health

摘　　要：目的观察吉西他滨联合多西他赛治疗耐药性乳腺癌的近期疗效及不良反应。方法 2008年6月至2012年3月对27例耐药性晚期乳腺癌采用吉西他滨1 000 mg/m2静脉滴注第1天、第8天;多西他赛75 mg/m2静脉滴注1 h,第1天;21 d为1个周期,连用2个周期后评价疗效和不良反应。结果 27例均完成2周期以上化疗,均可评价,其中5例完全缓解,13例部分缓解,6例稳定,3例进展,总有效率为66.7%。主要不良反应为胃肠道反应、骨髓抑制、皮疹,均可耐受。结论吉西他滨联合多西他赛治疗蒽环类耐药性晚期乳腺癌的近期疗效较好,不良反应可以耐受,值得进一步临床研究。Objective To observe the short-term efficacy and adverse reactions of gemeitabine combined with doeetaxel in the treatment of patients with anthracycline-resistant metastatic breast cancer. Methods Twenty-seven patients with anthraey- cline-resistant metastatic breast cancer hospitalized from June 2008 to March 2012 were selected and treated with gemcitabine 1 000 mg/m2 for injection on day 1 and day 2 ,simultaneously with intravenous docetaxel 75 mg/m2 for an hour on day 1.21 days regarded as one period, the efficacy and adverse reaction were assessed after two continuous periods of chemotherapy. Results All the patients completed more than two periods of chemotherapy and were available for evaluation,including 5 cases with complete response, 3 cases with partial response, 6 cases with stable disease and 3 cases with progression disease with the overall response rate of 66.7%. The main adverse reactions were gastrointestinal reaction, myelosuppression and rash, but all these adverse reactions were tolerable. Conclusion Gemcitabine combined with docetaxel in the short-term treatment of advanced breast can- cer is with better efficacy and the adverse reactions are tolerable, so it is worthy of further study clinically.

关 键 词：乳腺肿瘤 吉西他滨 多西他赛 药物耐受性 

分 类 号：R737.905[医药卫生—肿瘤]